ASH 2025: Ascentage Pharma Chairman & CEO Dajun Yang shares an update on the company's Bcl-2, lisaftoclax, which was recently approved in China and is in multiple global registration studies

blonca9
11 hours ago
1 min read

The therapy has shown single agent efficacy in patients who are refractory to BTKs. Plus, an update on global studies of the BCR-ABU/KIT, olverembatinib, and highlighting Ascentage's EED inhibitor.

Coverage brought to you by

Recent Posts

See All

ASH 2025: Kelonia Therapeutics presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation

$ASH 2025: MaaT Pharma's microbiome based treatment for refractory GVHD is in front of EMA right now for a possible 2026 approval - the pivotal data was presented in an oral at ASH this week$

ASH 2025: MaaT Pharma's microbiome based treatment for refractory GVHD is in front of EMA right now for a possible 2026 approval - the pivotal data was presented in an oral at ASH this week

ASH 2025: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know

ASH 2025: Ascentage Pharma Chairman & CEO Dajun Yang shares an update on the company's Bcl-2, lisaftoclax, which was recently approved in China and is in multiple global registration studies

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight